Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 12Small Cell Lung Carcinoma 5Nonsquamous Non-Small Cell Lung Cancer 2Neoplasms 2Carcinoma 2Advanced Lung Cancer 2Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Cancer Extensive Stage 1SCLC 1Respiratory Tract Diseases 1Resectable Non-small Cell Lung Cancer 1Resectable NSCLC 1Radiation Pneumonitis 1Osteosarcoma 1Non-small Cell Lung Cancer Metastatic 1Non-Squamous Non-Small Cell Lung Cancer 1NSCLC 1Multiple Primary Lung Cancer 1Lung Diseases 1Locally Advanced Non-Small Cell Lung Cancer 1IIIA Stage Non-small Cell Lung Cancer 1High-Risk Resectable NSCLC 1Brain Neoplasms 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1

Interventions

toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High-Risk Resectable NSCLC × sintilimab × Thoracic × Clear all
NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Completed
27 enrolled
Thoracic

High-Risk Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡